Related Papers
Respiratory medicine
Adverse events among COPD patients treated with long-acting anticholinergics and β2-agonists in an outpatient respiratory clinic
2016 •
Amélie Forget
Chronic obstructive pulmonary disease (COPD) is the fourth leading cause of death in Canada. Most patients with COPD receive long-term treatment with long-acting anticholinergics (LAAC) and/or long-acting β2-agonists (LABA). Adverse events (AEs) are also likely during long-term treatment with these medications. To evaluate the prevalence of AEs in COPD patients on LAAC and LABA in a real-world setting. We conducted a cross-sectional study of patients enrolled in the Registre de Données en Santé Pulmonaire (RESP) database, which records information on Canadian patients with asthma or COPD. COPD Patients completed a questionnaire about AEs that may be associated with LAAC and/or LABA. The prevalence of AEs and the corresponding 95% CI were calculated for three groups of patients (LAAC + LABA, LAAC alone, and LABA alone). Most patients with COPD (n = 154) were current or ex-smokers. Over 50% of patients were overweight or obese, and had an annual family income of less or equal to $42,0...
Acta Scientific Microbiology
Assessment of Safety in COPD Patients Receiving Long Acting β2- agonist in Addition to Long Acting Anticholinergics
2020 •
Aleena Alex
International Journal of COPD
Bronchodilators in COPD: Impact of ?-agonists and anticholinergics on severe exacerbations and mortality
2007 •
Shelley Salpeter
JAMA
Inhaled Anticholinergics and Risk of Major Adverse Cardiovascular Events in Patients With Chronic Obstructive Pulmonary Disease
2008 •
Sonal Singh, Curt Furberg
Clinical Reviews in Allergy & Immunology
Systematic Review of Clinical Outcomes in Chronic Obstructive Pulmonary Disease: β-Agonist Use Compared With Anticholinergics and Inhaled Corticosteroids
2006 •
Shelley Salpeter
BMJ Open Respiratory Research
Is the use of two versus one long-acting bronchodilator by patients with COPD associated with a higher risk of acute coronary syndrome in real-world clinical practice?
Lianne Parkin
BackgroundCardiovascular comorbidity is common among patients with chronic obstructive pulmonary disease (COPD) and there is concern that long-acting bronchodilators (long-acting muscarinic antagonists (LAMAs) and long-acting beta2 agonists (LABAs)) may further increase the risk of acute coronary events. Information about the impact of treatment intensification on acute coronary syndrome (ACS) risk in real-world settings is limited. We undertook a nationwide nested case–control study to estimate the risk of ACS in users of both a LAMA and a LABA relative to users of a LAMA.MethodsWe used routinely collected national health and pharmaceutical dispensing data to establish a cohort of patients aged >45 years who initiated long-acting bronchodilator therapy for COPD between 1 February 2006 and 30 December 2013. Fatal and non-fatal ACS events during follow-up were identified using hospital discharge and mortality records. For each case we used risk set sampling to randomly select up t...
Drugs
Do Inhaled Anticholinergics Increase or Decrease the Risk of Major Cardiovascular Events?
2009 •
Shelley Salpeter
International Journal of COPD
Beta-blockers use in patients with chronic obstructive pulmonary disease and concomitant cardiovascular conditions
Mohaned Egred
The mortality and incidence of chronic obstructive pulmonary disease (COPD) and coronary heart disease increase with age. Despite the clear evidence of beta blockers (BBs) effectiveness, there is a general reluctance to use them in patients with COPD due to a perceived contraindication and fear of inducing adverse reactions and bronchspasm. BBs are well tolerated in patients with cardiac disease and concomitant COPD with no evidence of worsening of respiratory symptoms or FEV1, and the safety of BBs in patients with COPD has been demonstrated, but their use in this group of patients remains low. The cumulative evidence from trials and meta-analysis indicates that cardioselective BBs should not be withheld in patients with reactive airway disease or COPD. Patients with COPD have a high incidence of cardiac events necessitating careful consideration of prophylactic treatment. The benefits of beta blockade in this group appear to outweigh any potential risk of side effects according to...
The American Journal of Medicine
Addition of anticholinergic solution prolongs bronchodilator effect of β2agonists in patients with chronic obstructive pulmonary disease
1996 •
Jerrold Kram
Heart (British Cardiac Society)
Cardiovascular outcomes with an inhaled beta2-agonist/corticosteroid in patients with COPD at high cardiovascular risk
2017 •
Sheldon Magder
Cardiovascular disease (CVD) and chronic obstructive pulmonary disease (COPD) often coexist. We assessed the effect of inhaled COPD treatments on CVD outcomes and safety in patients with COPD and at heightened CVD risk. The SUMMIT (Study to Understand Mortality and MorbidITy) was a multicentre, randomised, double-blind, placebo-controlled, event-driven trial in 16 485 patients with moderate COPD who had or were at high risk of CVD. Here, we assessed the prespecified secondary endpoint of time to first on-treatment composite CVD event (CVD death, myocardial infarction, stroke, unstable angina or transient ischaemic attack (TIA)) by Cox regression and by clinician-reported CVD adverse events across the four groups: once-daily inhaled placebo (n=4111), long-acting beta2-agonist (vilanterol (VI) 25 µg; n=4118), corticosteroid (fluticasone furoate (FF) 100 µg; n=4135) and combination therapy (FF/VI; n=4121). Participants were predominantly middle-aged (mean 65 (SD 8) years) men (75%) wit...
